Business
Premier Biomedical, Inc. Accomplishments and Recent News
Premier Biomedical, Inc. Accomplishments and Recent News.
About this update from Premier Biomedical Inc
[{"type":"text","content":"For Medical Treatments of Incurable and Hard To Cure Diseases Including Cancer, Muscular Dystrophy, and NeurofibromatosisEL PASO, Texas--(BUSINESS WIRE)-- Premier Biomedical, Inc. (PBI) is a publicly traded (OTCQB:BIEI) research-based company that intends to discover and develop medical treatments targeting the treatment of heretofore incurable and/or hard-to-cure diseases.The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects. We believe this method could be superior to current treatments which counteract symptoms or eliminate the presence of most illnesses, but often are accompanied by catastrophic or even fatal side effects. Premier’s “Subtractive” therapy is designed to eliminate the etiology agent(s) or modify the pathophysiological changes brought about by certain diseases, thereby reducing risks associated with conventional “Additive” therapy (i.e., adding chemicals to the body). The initial disease target is breast cancer, however, we believe this same methodology can also be applied in the future to treating other forms of cancer, Leukemia, Muscular Dystrophy, Cockayne Syndrome, Neurofibromatosis, Fibromyalgia, and Atherosclerosis. Collectively, these diseases represent over $700 billion in annual treatment costs today. This is a tremendous market opportunity for Premier’s methodology, and, many of these diseases can be orphan drug designated (regulatory fast track).Premier has developed a proprietary patented drug candidate, Feldetrex™. Based on our initial studies, we found Feldetrex™ to be another promising option for the comprehensive management of muscular and neuropathic pain, as well as chemical addiction. This unique drug combination is expected to deliver significant relief to patients, while presenting fewer, if any, side effects than alternate medications currently available. The annual market size for all proposed market segments for Feldetrex™ is over $20 Billion. The company strategy is to use the sales of Feldetrex™ to provide short term revenue and to fund our continuing technology development efforts.A recent study conducted by the Penn Biomedical Group (PBG) analyzed the potential market for Feldetrex™ versus entrenched competition, Lyrica®, Cymbalta® and Sevella®, who...